Loading INSM detail
Loading ticker data...
Loading INSM detail
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Chart data unavailable
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.
Park Capital Management LLC WI acquired a new position in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,989 shares of the biopharmaceutical company's stock, valued at approximately $1,042,000. Insmed comprises approximately
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued
Allspring Global Investments Holdings LLC lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 3.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 220,084 shares of the biopharmaceutical company's stock after selling 7,545 shares during the period.
Insmed Inc (NASDAQ:INSM) shares were last seen up 0.3% to trade at $164.03, after a price-target hike to $237 from $231 at Barclays.
Insmed remains a Buy, with enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Brinsupri's launch exceeded expectations, with Q4 revenues of $144.6M and management guiding for $1B in 2026 sales. TPIP offers differentiation in PAH/PH-ILD with once-daily dosing and encouraging Phase 2b data, supporting a $3B rNPV estimate.
Insmed (INSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
E. Ohman J or Asset Management AB purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,239 shares of the biopharmaceutical company's stock, valued at approximately $912,000. Other hedge funds and other institutional investors
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States.
Insmed (INSM) remains a "Strong Buy", driven by positive phase 3b ENCORE results for ARIKAYCE in 1st-line MAC lung disease and robust pipeline progress. INSM is positioned to expand ARIKAYCE's label to 1st-line MAC patients [200k+], convert accelerated to full approval for refractory MAC, and pursue Japanese label expansion. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis, with 2026 revenue guidance of at least $1 billion; ARIKAYCE 2025 sales reached $433.8 million, up 19% YoY.
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
